CANCER GENE THERAPY CLINICAL TRIALS

2006 ◽  
pp. 379-390
Author(s):  
EVANTHIA GALANIS
Author(s):  
Swapnil S. Talkar ◽  
Vandana B. Patravale

Background: According to the American Cancer Society, prostate cancer ranks second in terms of mortality and is a front-runner of newly detected cases. Conventional therapies neither eradicated cancer nor increased the life expectancy of patients obviating the need for less toxic as well as efficient therapies to treat cancer. Gene therapy alone or in combination with conventional therapies possesses a strong potential to combat cancer. Method: This review encompasses a brief note on the etiology and conventional therapy of prostate cancer with an emphasis on gene therapy and its suitability for the treatment of prostate cancer. Results: A comprehensive range of gene therapy approaches have been successfully explored for prostate cancer treatment in animal models and this has been well translated into early clinical trials. We have also discussed in brief about specific therapeutic genes and suitable vector systems for gene therapy in prostate cancer. Conclusions: Based on the results of these clinical trials, the application of gene therapy in prostate cancer therapeutics can be satisfactorily established.


2005 ◽  
Vol 4 (4) ◽  
pp. 315-330 ◽  
Author(s):  
Masato Yamamoto ◽  
David T. Curiel

The prognosis of patients with some kinds of cancers whose patients are often found unresectable upon diagnosis is still dismal. In these fields, development of a new therapeutic modality is needed and gene therapy represents one promising strategy. So far, numerous cancer gene therapy clinical trials based on these principles have been carried out and have shown the safety of such modalities, but have fallen short of the initial expectations to cure cancers. In this review, we would like to make a problem-oriented discussion of current status of cancer gene therapy research by using mainly gastrointestinal cancers as an example. In order to overcome obstacles for full realization of cancer gene therapy, numerous researches have been conducted by many researchers. Various cancer-selective and non-selective genes, as well as lytic viruses themselves have been employed for gene therapy. In the context of gene delivery method, different kinds of viral and non-viral strategies have been utilized. In addition, surrogate assays, such as soluble markers and imaging, have been developed for safer and more informative clinical trials. Many experiments and clinical trials to date have figured out current obstacles for the realization of an effective cancer gene therapy modality. Tireless efforts to overcome such hurdles and continuous infusion of novel concepts into this field should lead to break through technologies and the cure of the patients.


2006 ◽  
Vol 24 (2) ◽  
pp. 76-82 ◽  
Author(s):  
Daniel H. Palmer ◽  
Lawrence S. Young ◽  
Vivien Mautner

2007 ◽  
Vol 15 (6) ◽  
pp. 1042-1052 ◽  
Author(s):  
Svend O Freytag ◽  
Hans Stricker ◽  
Benjamin Movsas ◽  
Jae Ho Kim

1995 ◽  
Vol 6 (5) ◽  
pp. 565-573 ◽  
Author(s):  
Nancy A. Horn ◽  
Jennifer A. Meek ◽  
Gregg Budahazi ◽  
Magda Marquet

2003 ◽  
Vol 82 (1) ◽  
pp. 11-16 ◽  
Author(s):  
S. Xi ◽  
J.R. Grandis

Despite advances in surgery, radiotherapy, and chemotherapy, the survival of patients with oral squamous cell carcinoma has not significantly improved over the past several decades. Treatment options for recurrent or refractory oral cancers are limited. Gene therapy for oral cancer is currently under investigation in clinical trials. The goal of cancer gene therapy is to introduce new genetic material into target cells without toxicity to non-target tissues. This review discusses the techniques used in cancer gene therapy for oral squamous cell carcinoma and summarizes the ongoing strategies that are being evaluated in clinical trials.


Sign in / Sign up

Export Citation Format

Share Document